The USFDA has authorized the use of the bivalent formulation of the mRNA-1273 COVID-19 vaccine for children six years and older at least two months after completing primary or booster vaccination. The bivalent formulation of the BNT162b2 COVID-19 vaccine has been authorized for use in children of five years of age and above, at least two months after completing primary or booster vaccination.
Vaccine action The bivalent vaccines include an mRNA component of the original strain that evokes the immune response to protect against the original strain and the Omicron’s BA.4 and BA.5 lineages. Authorization was based on the following clinical data Immune response elicited by a single booster dose of the monovalent mRNA-1273 COVID-19 vaccine given to 250 participants (aged 12–17 years), at least five months after completing a two-dose primary series was comparable to the immune response to the…
